Pediatric Growth Hormone Deficiency Market – Global Industry Size, Share, Trends, Opportunity, & Forecast Segmented By Type (Congenital GH Deficiency, Acquired GH Deficiency, Idiopathic GH Deficiency), By Product (Powder, Solvent), By Application (Growth Hormone Deficiency, Idiopathic Short Stature, Turner Syndrome, Small For Gestational Age, Prader-Willi Syndrome, Others), By Drug (Genotropin, Humatrope, Norditropin Flexpro, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), By Region and Competition, 2020-2030F

Market Overview

Global Pediatric Growth Hormone Deficiency Market was valued at USD 3.87 Billion in 2024 and is expected to reach USD 6.41 Billion by 2030 with a CAGR of 8.77% during the forecast period. The Global Pediatric Growth Hormone Deficiency (PGHD) Market encompasses a range of products and services aimed at diagnosing and treating growth hormone deficiency in pediatric patients. This market plays a crucial role in addressing growth-related health issues in children and ensuring their optimal physical development.

The increasing prevalence of growth hormone deficiency (GHD), linked to brain injuries, genetic disorders, congenital conditions, and certain medical treatments, has heightened the demand for growth hormone therapies. According to NCBI, pediatric GHD is diagnosed in approximately 1 in every 3,500–4,000 children in the UK. Additionally, rising research and development (R&D) efforts in the growth hormone sector are further propelling market growth. For instance, in February 2022, Pfizer and OPKO’s Once-Weekly NGENLA™ (somatrogon) Injection received marketing authorization from the European Union for the treatment of pediatric growth hormone deficiency, marking a significant advancement in therapy options.

The growing awareness regarding the application of synthetic growth hormone therapy has significantly contributed to its adoption. Human growth hormone (hGH) plays a crucial role in stimulating reproduction, regeneration, and overall growth in individuals. The development of innovative recombinant human growth hormones is expected to further drive the growth hormone deficiency market. According to a research article published in Intractable & Rare Diseases Research (2018) by Xiaoxiao Cui et al., Turner Syndrome (TS) is a relatively common chromosomal disorder, occurring in 1 out of every 2,500 live female births. Notably, a majority of cases are reported in China, highlighting the regional prevalence of the condition.

Key Market Drivers

Increasing Prevalence of Pediatric Growth Hormone Deficiency (PGHD)

The increasing prevalence of Pediatric Growth Hormone Deficiency (PGHD) is a significant market driver for the Global Pediatric Growth Hormone Deficiency Market. This driver is underpinned by several factors, all of which have substantial implications for the market. A substantial portion of PGHD cases can be attributed to genetic factors. Children with a family history of growth hormone deficiency are at an increased risk of developing the condition themselves. This genetic link drives the prevalence of PGHD. As the understanding of genetic factors improves, genetic testing becomes more prevalent. This results in the identification of more at-risk individuals, contributing to a growing pool of diagnosed PGHD cases. Premature birth and low birth weight are risk factors for PGHD. Advances in neonatal care have increased the survival rates of preterm infants, but they may still face growth challenges due to hormonal imbalances. With advancements in medical technology, more premature infants are surviving and receiving medical attention. This has led to a higher likelihood of identifying growth hormone deficiencies in this patient group, further increasing the prevalence of PGHD. 

According to a article published in NCBI, the estimated prevalence of growth hormone deficiency (GHD) is approximately 2–3 cases per 10,000 people. GHD can result from structural pituitary abnormalities or cranial irradiation and often occurs alongside other features of hypopituitarism. Among the causes of adult-onset GHD, pituitary adenomas are the most commonly reported, followed by craniopharyngiomas, which account for approximately 57% of cases.

Diagnostic tools and techniques have advanced significantly over the years, enabling more accurate and timely identification of PGHD cases. These tools include growth charts, blood tests, and imaging studies. Enhanced diagnostic capabilities mean that cases that might have gone unnoticed in the past are now being detected. This translates to a higher number of diagnosed PGHD cases, directly impacting the demand for growth hormone therapy. Healthcare professionals are becoming more aware of PGHD and its symptoms. This heightened awareness leads to more comprehensive evaluations and testing for growth hormone deficiencies in children exhibiting related symptoms. As healthcare providers become more vigilant in screening for PGHD, they identify cases that may have previously been overlooked. This proactive approach contributes to the upward trend in PGHD prevalence.

Advancements in Growth Hormone Therapies

Advancements in Growth Hormone Therapies play a crucial role as a market driver in the Global Pediatric Growth Hormone Deficiency (PGHD) Market. These advancements are characterized by innovations in treatment modalities and formulations, and they significantly impact the growth and dynamics of the market. Rationale: One major advancement is the development of long-acting growth hormone formulations. These formulations allow for less frequent dosing, often just once a week, compared to daily injections required with traditional therapies. This improves patient compliance and convenience.

Long-acting formulations enhance the patient experience, making treatment more manageable and reducing the burden of frequent injections. As a result, more parents and caregivers opt for growth hormone therapy, leading to increased market demand. Biosimilars are biologic drugs that are highly similar to the reference product. They offer a more cost-effective alternative to branded growth hormone therapies while maintaining comparable safety and efficacy. The availability of biosimilars in the market can lead to competitive pricing, making growth hormone therapy more accessible to a wider patient population. This increased affordability drives the adoption of treatment and stimulates market growth. Advancements in genetics and pharmacogenomics have enabled the development of personalized growth hormone therapies. These treatments are tailored to an individual's genetic and physiological characteristics, optimizing their response to therapy. Personalized therapies provide improved treatment outcomes and fewer side effects, as they are customized to each patient's unique needs. This encourages healthcare providers to recommend and prescribe growth hormone therapy more frequently.

Innovations in drug delivery systems have made administering growth hormone therapies more convenient and less painful. These systems include needle-free devices, autoinjectors, and wearable infusion pumps. Patient comfort and ease of administration are significantly improved with these innovations. Parents and caregivers are more likely to adhere to treatment plans when they can administer therapy with minimal discomfort, boosting market demand.

Download Free Sample Report

Growing Healthcare Infrastructure and Access to Care

The growth of healthcare infrastructure and improved access to care is a significant market driver for the Global Pediatric Growth Hormone Deficiency (PGHD) Market. This driver is rooted in various factors that contribute to the expansion and accessibility of healthcare services. The construction and expansion of healthcare facilities, including hospitals, clinics, and specialty centers, contribute to increased access to medical care. This is particularly relevant for the diagnosis and treatment of pediatric health conditions, including PGHD.

With more healthcare facilities equipped to diagnose and manage PGHD, more children have access to specialized care. This expansion leads to a higher number of diagnosed cases and greater demand for growth hormone therapy. Governments and organizations worldwide have initiated programs to improve healthcare access in rural and underserved areas. These initiatives aim to bridge the gap between urban and rural healthcare services. As rural communities gain better access to healthcare facilities and services, children in these areas are more likely to be screened for and diagnosed with PGHD. This contributes to an increase in the overall prevalence of the condition and subsequently drives market growth.

Expanding health insurance coverage, both publicly and privately, ensures that more individuals and families have access to medical services, including the diagnosis and treatment of PGHD. Health insurance coverage reduces the financial burden on parents and caregivers when seeking medical care for their children. This encourages more families to seek medical attention for suspected growth hormone deficiencies, thereby boosting market demand. Many governments have introduced healthcare initiatives aimed at improving child health and well-being. These programs often include early childhood screenings and access to essential medications. Government-sponsored healthcare initiatives play a pivotal role in diagnosing and treating PGHD at an early stage. This leads to timely interventions and a higher prevalence of diagnosed cases, contributing to market growth.

Heightened Awareness and Patient Advocacy

Heightened awareness and patient advocacy play a pivotal role as a market driver for the Global Pediatric Growth Hormone Deficiency (PGHD) Market. These factors are instrumental in increasing the recognition of PGHD, driving early diagnosis, and promoting the importance of treatment. Patient advocacy groups, healthcare organizations, and pharmaceutical companies often collaborate to conduct awareness campaigns and educational initiatives. These campaigns aim to inform healthcare professionals, parents, and the general public about PGHD, its signs, symptoms, and the importance of early intervention.

Increased awareness prompts healthcare providers to consider PGHD in their differential diagnosis for children with growth issues. Parents and caregivers are also more likely to seek medical evaluation if they recognize potential symptoms, leading to earlier diagnosis and treatment initiation. Patient advocacy groups emphasize the significance of early diagnosis in PGHD management. They stress the potential benefits of early intervention in improving a child's growth trajectory and overall health. Heightened awareness regarding the importance of early diagnosis encourages healthcare professionals to be proactive in screening for PGHD. As a result, more children are diagnosed at an earlier stage, increasing the demand for growth hormone therapy. Patient advocacy groups often collaborate with pharmaceutical companies and research institutions to support studies and clinical trials related to PGHD. Their involvement accelerates the development of new treatment options and therapies. Research and development efforts supported by patient advocacy groups lead to the introduction of innovative therapies, including improved growth hormone formulations. These advancements provide additional treatment options, expanding the market and meeting evolving patient needs.

Key Market Challenges

High Cost of Growth Hormone Therapy

One of the primary challenges is the high cost associated with growth hormone therapy. These therapies are often expensive, requiring regular injections over an extended period. The cumulative cost of treatment can be a significant financial burden for patients and their families.

The cost barrier can deter some families from pursuing growth hormone therapy for their children, even when it is medically necessary. This can limit the market's growth potential, especially in regions with limited access to health insurance or government-sponsored healthcare programs.

Regulatory and Approval Hurdles

The development and approval of growth hormone therapies involve stringent regulatory processes and clinical trials. Meeting these regulatory requirements can be time-consuming and costly for pharmaceutical companies. Additionally, obtaining approvals for pediatric indications may present unique challenges.

Regulatory hurdles can delay the introduction of new therapies to the market. Delays in approval can limit treatment options for patients and result in a less competitive landscape, potentially impacting accessibility and pricing.

Limited Awareness and Diagnosis Challenges

Despite efforts to raise awareness, many cases of PGHD still go undiagnosed. The condition's symptoms, such as short stature, can overlap with normal variations in growth, leading to delayed or missed diagnoses. Additionally, awareness about PGHD may be lower in certain regions.

Limited awareness and diagnosis challenges mean that a significant number of PGHD cases may remain untreated. This not only hampers patient outcomes but also restricts the growth of the market, as undiagnosed cases do not contribute to the demand for growth hormone therapies.

Key Market Trends

Biological and Biosimilar Growth Hormone Therapies

The trend towards biological and biosimilar growth hormone therapies is gaining traction in the PGHD market. Biologicals are produced using living cells and are highly specific to their targets. Biosimilars are highly similar to already-approved biologicals but may be more cost-effective.

Biosimilars typically cost less than the original biologicals, making growth hormone therapy more affordable for patients and healthcare systems. As more biosimilars enter the market, competition increases, which can lead to price reductions and increased accessibility. The availability of biologicals and biosimilars provides physicians with a wider range of treatment choices, allowing for personalized therapy plans.

Telemedicine and Remote Monitoring

The adoption of telemedicine and remote monitoring technologies is becoming a prominent trend in the PGHD market. These technologies enable healthcare providers to conduct consultations, monitor patients, and manage treatment remotely.

Telemedicine overcomes geographic barriers, ensuring that patients in remote or underserved areas can access specialized PGHD care. Telemedicine enhances the convenience of follow-up appointments and monitoring, reducing the need for frequent in-person visits. Remote monitoring tools engage patients and caregivers in managing PGHD, fostering adherence and facilitating data-driven decision-making.

Personalized Medicine and Genetic Testing

Personalized medicine and genetic testing are emerging as influential trends in the PGHD market. These approaches involve tailoring treatment based on an individual's genetic and physiological characteristics.

Personalized medicine allows for more precise treatment, optimizing the therapeutic response and minimizing potential side effects. Genetic testing can identify specific gene mutations or variations associated with PGHD, aiding in diagnosis and treatment decisions. Ongoing research in genomics and pharmacogenomics is driving the development of more targeted and effective therapies for PGHD.

Segmental Insights

Type Insights

Based on Type, the congenital growth hormone deficiency (GHD) segment emerged as the dominant player in the global market for Pediatric Growth Hormone Deficiency. Congenital GHD, which is present at birth or detected during early childhood, represents a significant portion of diagnosed cases, and its prevalence is influenced by various clinical and demographic factors.

Congenital GHD is characterized by the absence or malfunction of the pituitary gland or hypothalamus responsible for growth hormone production. This condition often manifests in infancy or early childhood, leading to earlier diagnosis and intervention. Early diagnosis allows for prompt initiation of growth hormone therapy, which is crucial for achieving optimal growth outcomes. Physicians and caregivers are more likely to identify congenital GHD because of noticeable growth delays and developmental concerns, driving the dominance of this segment.

Congenital GHD is more prevalent than acquired GHD in the pediatric population. While acquired GHD can result from factors such as tumors or radiation therapy, congenital GHD is typically attributed to genetic or developmental issues. The higher prevalence of congenital GHD naturally leads to a larger patient population within this segment. A larger patient pool means greater demand for growth hormone therapy, further solidifying the dominance of the congenital GHD segment in the market. Congenital GHD often has genetic underpinnings, and it can run in families. Children born to parents with a history of GHD or genetic mutations related to growth hormone production are at a higher risk of developing congenital GHD. Genetic and familial factors contribute to a consistent influx of diagnosed cases within the congenital GHD segment. Families with a history of GHD are more likely to seek medical evaluation for their children if they suspect growth issues, further boosting the segment's dominance. These factors are expected to drive the growth of this segment.

Drug Insight

Based on Drug, the Norditropin segment emerged as the dominant player in the global market for Pediatric Growth Hormone Deficiency. Norditropin is a brand of recombinant human growth hormone (rhGH) therapy, and it has established itself as a prominent choice for treating pediatric GHD. Norditropin has a long-standing history of proven clinical efficacy in stimulating growth and improving height outcomes in children with GHD. Numerous clinical trials and real-world studies have consistently demonstrated its effectiveness. The well-established clinical efficacy of Norditropin instills confidence among healthcare providers, parents, and caregivers. Its track record as an effective treatment option solidifies its dominance in the market.

Norditropin offers a range of formulations, including injectable pens with varying concentrations and delivery options. These formulations cater to different patient needs, providing flexibility in dosing and administration. The availability of diverse formulations allows healthcare providers to tailor treatment plans to individual patients. This versatility makes Norditropin suitable for a wide range of pediatric GHD cases, enhancing its market dominance. Norditropin's injectable pens are designed for ease of use, offering patient-friendly features such as pre-filled cartridges, simple dose adjustments, and ergonomic designs. These attributes enhance patient comfort and convenience. Patient-friendly delivery systems encourage better adherence to treatment regimens, as they reduce the fear and discomfort associated with injections. This leads to more successful outcomes and reinforces Norditropin's dominance in the market. These factors collectively contribute to the growth of this segment.

Download Free Sample Report

Regional Insights

North America emerged as the dominant region in the global Pediatric Growth Hormone Deficiencys market, holding the largest market share. The United States boasts a highly advanced healthcare infrastructure, including a robust network of specialized pediatric hospitals, clinics, and healthcare providers. This infrastructure allows for comprehensive diagnosis and treatment of PGHD. The availability of state-of-the-art healthcare facilities and expertise in pediatric endocrinology makes the United States a dominant player in the PGHD market. It ensures that a substantial number of PGHD cases are diagnosed and treated effectively. 

The United States places a strong emphasis on early diagnosis and intervention in pediatric healthcare. Routine health check-ups and well-child visits enable the early identification of growth-related issues, including PGHD. The culture of early diagnosis ensures that a significant proportion of PGHD cases are identified at a young age, enabling timely interventions with growth hormone therapy. This proactive approach contributes to the dominance of the region. Health insurance coverage in the United States, although complex, often includes coverage for pediatric healthcare needs, including growth hormone therapy. This reduces financial barriers for many families. Improved access to care, driven by insurance coverage and financial support, ensures that children with PGHD have the means to seek diagnosis and treatment. This positively impacts the prevalence of diagnosed cases and the market's growth. Growth hormone deficiency (GHD) is a rare condition, affecting fewer than 1 in 3,000 to 1 in 10,000 children in the United States, according to the American Academy of Pediatrics. This low prevalence, combined with rising awareness, advancements in diagnostic capabilities, and increased access to treatment, is driving growth in the North American Pediatric Growth Hormone Deficiency Market. Additionally, the presence of leading pharmaceutical companies, robust healthcare infrastructure, and ongoing research initiatives further supports market expansion in the region.

Recent Developments

• In January 2025, Pfizer Korea ends promotion of once-weekly growth hormone therapy Ngenla due to market uncertainty.
• In December 2024, JCR Pharmaceuticals Co., Ltd. announced that the first patient has been dosed in the Phase III clinical trial of JR-142 (INN: redalsomatropin alfa) in Japan, marking a significant milestone in the development of this innovative treatment. JR-142 is a long-acting growth hormone therapy and is being studied in patients with pediatric growth hormone deficiency.
• In December 2024, Ascendis Pharma A/S announced that the U.S. Food & Drug Administration (FDA) has accepted for review its supplemental Biologics License Application (sBLA) in adult growth hormone deficiency (GHD) for TransCon hGH (lonapegsomatropin-tcgd; marketed as SKYTROFA® for pediatric GHD). The FDA set a Prescription Drug User Fee Act (PDUFA) goal date of July 27, 2025.
• In March 2024, Handok and Genexine announced that their long-acting growth hormone for children, HL2356 (GX-H9), received orphan drug designation from the Ministry of Food and Drug Safety during its development phase.
• In November 2023, Lumos Pharma, Inc. reported positive topline results from its Phase 2 OraGrowtH210 dose-finding trial and Phase 2 OraGrowtH212 Pharmacokinetic/Pharmacodynamic (PK/PD) trial. Both studies successfully met their primary and secondary objectives. The OraGrowtH210 Trial demonstrated an annualized height velocity (AHV) of 8.2 cm/year at six months and 8.0 cm/year at 12 months in patients receiving a 1.6 mg/kg dose of orally administered LUM-201. These results align with historical data on moderate pediatric growth hormone deficiency patients and remain within the targeted 2 cm/year margin compared to the injectable recombinant growth hormone arm.
• In August 2023, Novo Nordisk announced that semaglutide 2.4 mg, a once-weekly injectable GLP-1 receptor agonist, reduced the risk of major cardiovascular events by 20% in adults with overweight or obesity who had at least one risk factor for cardiovascular disease.
• Lilly is investing $1.6 billion in the construction of two new manufacturing facilities in Indiana. The new facilities are expected to create 200 new jobs and increase Lilly's production capacity for active pharmaceutical ingredients, including the ingredients for Mounjaro.   
• Merck KGaA is investing USD24.51 million in the expansion of its cell culture media production facility in Kansas, USA. The company is also investing USD74.60 million in the expansion of its reagent manufacturing facility in Nantong, China. These investments are expected to increase Merck KGaA's production capacity for key pharmaceutical ingredients and reagents.

Key Market Players

• Novo Nordisk A/S
• Eli Lily and Company
• Novartis AG
• Merck KgaA
• Pfizer Inc.
• Ferring B.V
• Genentech Inc
• BioParteners GmbH
• LG Chem Ltd.
• Ipsen Pharma

Report Scope:

In this report, the Global Pediatric Growth Hormone Deficiency Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Pediatric Growth Hormone Deficiency Market, By Type:

o   Congenital GH Deficiency

o   Acquired GH Deficiency

o   Idiopathic GH Deficiency

• Pediatric Growth Hormone Deficiency Market, By Product:

o   Powder

o   Solvent

• Pediatric Growth Hormone Deficiency Market, By Application:

o   Growth Hormone Deficiency

o   Idiopathic Short Stature

o   Turner Syndrome

o   Small For Gestational Age

o   Prader-Willi Syndrome

o   Others

• Pediatric Growth Hormone Deficiency Market, By Drug:

o   Genotropin

o   Humatrope

o   Norditropin Flexpro

o   Others

• Pediatric Growth Hormone Deficiency Market, By Distribution Channel:

o   Hospital Pharmacies

o   Retail Pharmacies

o   Online Pharmacies

o   Others

• Pediatric Growth Hormone Deficiency Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia-Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

§  Kuwait

§  Turkey

§  Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pediatric Growth Hormone Deficiency Market.

Available Customizations:

Global Pediatric Growth Hormone Deficiency market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Induration

• Detailed analysis and profiling of additional market players (up to five).

Global Pediatric Growth Hormone Deficiency Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]